Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SPLENDOUR: Added denosumab in first line adv NSCLC treatment

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 22.10.18
Views: 1597

Dr Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Dr Solange Peters speaks with ecancer at ESMO 2018 in Munich about a randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC.

She outlines the rationale of the trial, based on some observed survival benefit alongside bone protection in other patients, which was ultimately found to be negative.

Besides the lack of impact of added denosumab in NSCLC treatment, Dr Peters highlights the emerging role of targeted therapies which have supplanted the older treatment paradigms.

Dr Peters also spoke with ecancer about the Women 4 Oncology initiative to improve representation of women in cancer research.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation